Purpose The purpose of this study was to test the reliability of the Swedish version of the Oxaliplatin-Associated Neurotoxicity Questionnaire (OANQ) administrated throughout a self-reported mobile phone-based system, a pilot study. Methods Twenty-three patients from two university hospitals and two regional hospitals who had been treated with oxaliplatin were included through purposive sampling between autumn 2013 to autumn 2014. A test-retest was performed through a mobile phone-based system, with a recall period of 1 h to determine the reliability of the questionnaire. Results Internal consistency was strong for the three domains of the scale (α > 0.840). The statistical analyses for the testretest indicated that the OANQ was stable. Intraclass correlation (ICC) for symptom items and effect on daily activities items showed an overall excellent reproducibility at 69 and 83 %, respectively. The weighted kappa for symptom items and daily activities items showed an overall almost perfect agreement at 59 and 52 %, respectively. A paired samples t test did not reveal any significant differences between the two measures. Conclusions The OANQ was tested and considered a reliable assessment for capturing the oxaliplatin-induced peripheral neurotoxicity (OIPN) in patients receiving oxaliplatin. However, further reliability testing of the OANQ is needed.
Introduction
A common treatment in advanced colorectal cancer (CRC) patients is a combination of different chemotherapeutic agents. Oxaliplatin is one of these drugs and it is frequently used today, usually combined with 5-fluorouracil (5-FU) and folinic acid (leucovorin) [1, 2] . Survival among patients with CRC has been shown to improve when oxaliplatin is added to the treatment, even when the patient is in later stages of the disease when diagnosed [3] .
Oxaliplatin is known to be highly neurotoxic [4, 5] and neurotoxic symptoms occur in the majority of patients treated with oxaliplatin [6] . Severe neurotoxic symptoms affect the patient's daily life in many ways and are associated with depression and affected quality of life [4] . It is known that the grade of neurotoxicity is strongly dose related [7] .
There are a number of studies that have shown that the neurotoxic side effects can be permanent and that the patients can struggle for many years after the treatment is finished [7] [8] [9] . It is also known, in comparison with other combinations, that patients receiving a combination that includes oxaliplatin have their symptoms for a longer time than patients receiving other combinations [5] . Oxaliplatin has recently been introduced in the treatment of other forms of cancer in the gastro-intestinal tract (GI tract), such as oesophagus, gastric, and pancreatic cancer [2, 10, 11] .
Several studies have investigated different strategies to eliminate or reduce the neurotoxic symptoms [11, 12] . Following that, ASCO guidelines state that there are no excising agents to prevent chemotherapy-induced peripheral neuropathy (CIPN) [13] . For managing existing CIPN, duloxetine has showed positive effects on CIPN pain but also decreased numbness and tingling symptoms [13, 14] .
Identifying risk patients
It is of great importance to identify the patients who are at risk of developing high-grade neurotoxicity [2] . Identification can eliminate the risk of developing chronic neurotoxic symptoms with functional impairment [12] . Nurses have a key role to provide information to patients and also to help them identify and report early signs of neurotoxicity [1] . Health professionals require valid assessments to capture early signs of neurotoxicity during and after oxaliplatin treatment [1] .
In cancer care, mobile phones are becoming more widely used in the assessment, monitoring, and management of symptoms [15] [16] [17] . Cancer outpatients have positive experiences of reporting chemotherapy-related symptoms using a mobile phone [16] . These experiences include improvements in the management of their symptoms and better communications with health care professionals, and patients also felt more secure when their symptoms were monitored [16] . Nurses have also experienced benefits since this new technology allows them to provide early interventions to patients during chemotherapy treatment [18] .
There are several established assessment scales to grade and report chemotherapy-induced peripheral neuropathy (CIPN), which is an umbrella term [19] . The designs of the CIPN assessments vary and they are sometimes grouped according to design, such as objective scales of common toxicity criteria (CTC), self-reported assessment scales, and drugspecific assessment scales [19] . The different regimes of chemotherapy present a challenge to the development of assessment scales detecting symptoms of CIPN. Oxaliplatin treatment has shown specific side effects which highlight the need for an oxaliplatin-specific assessment. The Functional Assessment of Cancer Therapy/Gynaecologic Oncology group, Neurotoxicity (FACT/GOG-Ntx) has been developed to better capture oxaliplatin-specific symptoms by adding one oxaliplatin-specific item to the scale [20] . Leonard et al. [21] pointed out the need for focused questions to capture to what extent OIPN affects daily activities. An exploratory research questionnaire was developed to capture the variety and locations of symptoms that patients undergoing oxaliplatin treatment were reporting. The questionnaire was intended to better quantify the drug-specific cold-related neuropathy symptoms, both acute and persistent, that are typical for oxaliplatin [21] .
Description of the oxaliplatin-associated neurotoxicity questionnaire
The questionnaire was not given an official name by the authors [21] , and therefore, it has different names in various clinical trials [19, 22, 23] . In this study, we decided to name the questionnaire the Oxaliplatin-Associated Neurotoxicity Questionnaire (OANQ).
The OANQ is divided into three sections corresponding to the side effect/symptom locations: upper extremities, lower extremities, and the face/mouth area. The first part of the assessment establishes whether the patient has experienced the specific symptoms, yes or no. If the answer is yes, the patient grades the severity of the symptom-hardly any to very much. Then the symptom is graded on how it affects the patient's daily activities-hardly at all bothered to extremely bothered in a functional sense. The scale ranges from 1 to 5 with a higher score indicating greater severity of the symptom and affects daily activities. The original OANQ is in English [21] and was translated to Swedish and adjusted to Swedish settings [24] . The translation of the OANQ to Swedish and back translation to English was conducted in three steps [25, 26] . Before the instrument was translated and adapted, the research team obtained permission from the authors of the instrument.
Validity of the OANQ
The OANQ was constructed from observational studies, experiences in clinical practice, and interviews with patients undergoing chemotherapy treatment with oxaliplatin (21; personal communication, 2014). The mentioned method used to elaborate the questionnaire indicates strong content validity [27] . In 2013, a predetermined protocol influenced by the Swedish version of the OANQ was used in a retrospective study of patients with colorectal cancer treated with oxaliplatin-based adjuvant chemotherapy [24] . The study aimed to investigate the presence of documented neurotoxic side effects in the patients' medical records. Free descriptions of the physician's estimation of the patient's neurotoxic symptoms in the medical records were analyzed. All symptoms in the predetermined protocol influenced by the Swedish version of the OANQ were found in the medical records except Bheat sensitivity^ [24] . This finding also strengthens the content validity of the questionnaire [27] . A formal validity of the OANQ was evaluated by a comparative analysis with the valid FACT/GOG-Ntx assessment scale [22] . Pearson's correlation analysis was carried out and showed a significantly negative correlation between the FACT/GOG and the OANQ (−0.73; p<0.001) and the Ntx subscale and the OANQ (−0.84; p<0.001) indicating a significant negative impact of patient-reported neuropathy symptoms on daily activities and quality of life. That showed that both instruments assessed a similar construct. The trial suggested further studies to evaluate the validity and reliability of the OANQ [22] . A need for reliability testing was revealed in a larger research project, which the present study is a part of. Therefore, the aim of this pilot study was to test the reliability of the Swedish version of the OANQ administered throughout a self-reported mobile phone-based system.
Patients and methods

Patients
The participants were selected through purposive sampling between autumn 2013 to autumn 2014. The participants were admitted from four oncology clinics: two university hospitals and two regional hospitals in the south of Sweden. A patient was eligible to participate if he/she fulfilled the following criteria: had ongoing treatment with oxaliplatin, was at least 18 years of age, able to read and write Swedish, was physically and psychologically fit to participate, and provided written informed consent. Exclusion criteria were patients who had diabetes, recognized neurotoxicity, and reduced cognitive function and also patients who had medications that could potentially cause peripheral neurotoxicity or had previously received any neurotoxic chemotherapy. The participants also required a mobile phone with access to the Internet and the capability to use the mobile phone-based system. Of all the patients asked, 24 participants were included and 23 participants performed the test-retest. One participant was excluded due to dropout. Many patients declined participation because of their general condition. The participants received both verbal and written information before they were admitted to the study. The participation was voluntary and the patients were able to end their participation at any time. Confidentiality was guaranteed throughout the study and informed consent to participate was written. Ethical approval was obtained from the Regional Ethical Review Board (record no: 2012/301-31).
Measurements
A test-retest of the Swedish mobile phone version of the OANQ was performed to evaluate the reliability of the questionnaire. The research group also modified and adjusted the Swedish version of the OANQ to fit a mobile system using Circadian Questions (CQ) ©, 21:st Century Mobile AB (http://www.cqmobil.se). In the adjustment process, some of the questions were condensed to fit the mobile display, but this did not interfere with the content of the questionnaire. Example, difficulty identifying objects in your hand (i.e., coin)/difficulty identifying, i.e., a coin in your hand.
The time interval between the two measures was predetermined to be 1 h. The date and time of the test-retest was arranged in advance to make sure that the participants, if necessary, were able to get assistance with technical issues by CQ staff monitoring the answers. The patients were instructed to answer the questionnaire as it applied to the present time, and not retrospectively. The answers from patients were directly sent via their mobile phone platform to the CQ database and were immediately accessible by the research team.
Statistical analysis
The test-retest reliability of the OANQ was assessed by paired samples t test, intraclass correlation (ICC), and weighted kappa. Cronbach's alpha was used to address the internal consistency. ICC is used for replicating measures from the same subject to estimate reproducibility. The ICC ranges between 0 and 1, where p<0.4 indicates poor reproducibility, 0.4≤p<0.75 indicates fair to good reproducibility, and p>0.75 indicates excellent reproducibility [28] . The weighted kappa is also used to estimate reproducibility by quantifying the concordance of the same subject for repeated measures [28] . The weighted kappa ranges between 0 and 1 and the kappa value is interpreted as follows; p<0 less than chance agreement, 0.01≤p<0. 20 [29] . For the paired samples t test, p<0.05 was considered significant. The statistical software STATA 12.1 (StataCorp, college station, TX, USA) was used to calculate the weighted kappa. SPSS, the statistical package version 20 (SPSS Inc., Chicago, IL, USA) for Mac, was used to assess the Cronbach's alpha, paired samples t test, and ICC.
Results
Twenty-three patients completed the test-retest and were therefore eligible for analysis. The data contains nine (0.7 %) missing answers distributed on different items. Due to the small number of missing values, no imputations were made.
Patient characteristics
The demographics and characteristics of the participants are presented in Table 1 . The distribution between male and female was almost equal and the majority of the patients were diagnosed with CRC. 
Test-retest
Weighted kappa statistics and ICC statistics for each item are presented in Table 2 . ICC for symptom items-69 % indicates excellent reproducibility, 24 % fair to good reproducibility, and 7 % poor reproducibility. ICC for affect on daily activities-items-83 % indicates excellent reproducibility, 10 % fair to good reproducibility, and 7 % poor reproducibility. Weighted kappa for symptom items-59 % almost perfect agreement, 28 % substantial agreement, 10 % moderate agreement, and 3 % fair agreement. Weighted kappa for affect on daily activities items-52 % almost perfect agreement, 38 % substantial agreement, 7 % moderate agreement, and 3 % fair agreement. Table 3 presents the paired samples t test for the three domains of the two tests. No significant differences were found. 
Internal consistency
The standardized Cronbach's coefficient (Cronbach's alpha) was calculated to evaluate the internal consistency of the 29-item OANQ and its domains. These figures are presented for each domain and in total in Table 4 . Internal consistency was good, indicating that the domains as well as the scale in total had good reliability.
Discussion
The need for an OIPN-specific assessment to address the exact symptom type and location has been highlighted in previous studies. The statistical analysis shows overall strong reliability for the OANQ and indicates that the questionnaire can be useful for monitoring and following up on OIPN symptoms. The internal consistency was strong (α>0.840) for each symptom domain (n=9-10). Cronbach's alpha for all 29 items was α>0.9 and corresponded with the well-known problem with multi-item scales and the calculation of internal consistency. Cronbach's alpha can easily increase just by adding items [30] , since the number of items is squared in the equation [31] . Since some of the symptoms can occur in different areas/locations of the body, some items reappear in the three domains. The authors therefore consider the Cronbach's alpha for each symptom domain to be the main focus. The test-retest statistics for each item revealed that two items, BDifficulty feeling hot things?^and BBurning pain or discomfort without cold?,^both in the upper extremity, showed poor reproducibility compared to the other items of the scale. This result could be explained by the small sample size and by the fact that a large variation in one participant's answer would therefore affect the ICC and weighted kappa in general. Concerning the missing items, they were distributed over different items and would therefore not seem to be consistent.
Purposive sampling is suitable for evaluation and effective presentation of newly developed instruments, since the sample is selected from the researchers' knowledge of the population. To make generalizations from a study's results, a probability sampling, such as randomized sampling, is needed [32] . The recruitment of cancer patients was challenging, which has also been seen and highlighted in previous studies [33] [34] [35] . This group of patients is often frail, undergoing tough and demanding treatment regimens, and also undergoing the psychological trauma of a potential life threat. To be part of a study in this difficult period of life can be overwhelming. This was also seen in the present study, since many of the patients did not meet the inclusion criteria Bto be physically and psychologically fit to participate.Ŵ hen it comes to sample size, there is a lack of golden standard. The sample size in our study (n=23) may seem relatively small in relation to the large number of patients receiving oxaliplatin for different malignancies. Focusing too much on sample size creates great challenges for researchers of uncommon diseases or studies with a small recruitment [36] . It is also interesting to discuss the importance of the sample size when reliability is the main focus, as in psychometric studies, rather than different scores and how they change over time. Hobart et al. [36] calculated that reliability testing is stable in sample sizes ≥20, which would be suitable in smaller studies, such as pilot studies. That study also mentioned that these results should be interpreted with caution. The different characteristics of a scale and how these would influence the stability of the reliability tests was investigated in the same research [36] . The findings of stability in relation to sample size were not influenced by the number of items, the number of subscales, or the number of response options [36] . Even though the sample size in our study was small, the population seemed heterogeneous according to the distribution of sex and age and the distribution of malignancies. The study population is transmittable to clinical settings since the largest group to be given the treatment comprised colorectal cancer patients (colorectal n=21, cardia n=1, esophagus n=1). This distribution of patients is similar to the study population in the larger research project.
The recall period for test-retest measures must correspond to the characteristics of the phenomenon of the study and the purpose of the assessment which explains why there is no single recall period that is best for all phenomena [30, 37] . It is important to be aware of patient's possibilities to remember and also the potential risk of change in the patient's clinical status in the recall period [30] . Although 1 h would seem to be a short retest interval, the authors believe that it is very unlikely that the patients would remember their answers to all 29 items. OIPN is a complex phenomenon in the sense that it can vary in duration and fluctuate in different environments (i.e., warm/cold temperatures) [20] . The time interval was estimated to 1 h to make sure that the patients were stable in the interim period and to minimize the chance of a real change in the construct. It is not unlikely that the poor reproducibility of the two items in the test-retest was caused by a true change in the symptom experience.
A majority of the patients receiving oxaliplatin suffer from neurotoxic symptoms, and yet there is still no well-accepted and effective treatment [38] . This fact highlights the importance of a valid assessment to identify patients at risk. As been revealed in previous studies [39, 40] , the symptoms are often minimized by the patients and also by health professionals. One explanation could be the lack of valid instruments to evaluate and asses the OIPN symptoms, which could create a barrier in the communication between the health professionals and the patients. This further highlights the great need for an instrument for use in clinical practice. This would allow the health professionals to guide the patients in managing the symptoms and to carry out follow-ups continuously, during and after treatment. The follow-ups are especially important since it is known that these patients have an increased risk of developing chronic neurotoxic symptoms [41] . It has also been revealed in previous studies that the use of a self-reporting instrument has positive effects on the conversation between patients and health professionals [42] . The patients also experience an increased interest from the health professionals, and this makes it easier for them to talk about the symptoms [42] .
Distributing a self-reported instrument through a mobile phone-based platform could have benefits, as increased usefulness and accessibility, regarding both symptom reporting and follow-ups. There is only limited research on using technology in cancer follow-up, but the available research indicates that it can be valuable [43, 44] . New technologies can have positive effects when used in the follow-up of cancer patients, such as patient empowerment and satisfaction [43] . Nurses have positive experiences of using an interactive tailored patient assessment application in the support of cancer patients since it contributes to patient-centered care [44] .
Further testing of the use of the mobile phone-based platform in the present study will be published elsewhere as a part of the bigger research project.
Our study has limitations and strengths. First, the sample size is small, which could affect the interpretation of the results. Therefore, the results should be applied with caution, even though they may provide guidance. Potentially, the biggest challenge further studies will face in establishing reliability will be the recruitment of cancer patients. The sampling method in our study could be seen as a limitation, since a probability sample is necessary in order to generalize the results to the general population receiving oxaliplatin treatment. Purposive sampling was used to meet the patient characteristics and was suitable for the purpose of this pilot study. Since this is a pilot study, the authors recommend further testing of OANQ in a larger sample and with a randomized sampling method, to make the results more reliable. The reliability of the OANQ has been thoroughly addressed with well-known measurements, which strengthens the results. The main focus of this study was to evaluate the reliability of the OANQ. To further increase the usefulness of the instrument, future studies should focus on its sensitivity and specificity.
In conclusion, the OANQ was tested and considered a reliable self-reporting assessment to capture the OIPN in patients receiving oxaliplatin. A valid and reliable assessment scale can contribute to the monitoring and follow-up of oxaliplatin treatment and may help nurses to guide patients in self-care actions. However, further reliability testing of the OANQ is needed.
